Elena I. Prokopenko

Elena I. Prokopenko

Auto-generated profile, based on publicly available information

Elena I. Prokopenko

M.F. Vladimirsky Moscow Regional Scientific Research Clinical Institute

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1999 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
SJSteven F. Josephs
Steven F. Josephs
JZJiemin Zhou
Jiemin Zhou
XFXiangming Fang
Xiangming Fang
RARamon Alemany
Ramon Alemany
CBCristina Balagué
Cristina Balagué
WZWei-Wei Zhang
Wei-Wei Zhang
Hemophilia A and B are the most common bleeding disorders caused by deficiencies of clotting factors VIII and IX, respectively, both of which are X-linked with a recessive heredity.1 Replacement of the deficient factors with frequent intravenous injections of plasma concentrates or recombinant proteins is the standard treatment for these diseases.2 Great efforts have been made for nearly a decade toward developing experimental gene therapy for these diseases and aiming at the development of a medical intervention that is more effective and convenient than the currently available replacement therapies.3 Hemophilia is a suitable clinical model for the development of gene therapy products and has a number of advantages: 1) there is a simple and well defined cause-and-effect relationship between the protein deficiencies and bleeding symptoms; 2) tissue-specific expression and precise regulation of the transgenes are not necessary; 3) well characterized animal models are available for preclinical studies; 4) an unequivocal endpoint for product efficacy can be assessed in clinical trials; and 5) even 1% to 5% of the normal physiological levels of the proteins is therapeutic. For gene therapy of hemophilia, the most challenging hurdle, with respect to the long-term expression of the deficient proteins at adequate levels, is the development of a suitable gene delivery system. Technologies have been evolving from ex vivo to in vivo approaches, from initial use of retroviral vector to recent application of adenviral (Ad) or adeno-associated virus (AAV) vector, demonstrating progress from early results of transient low-level expression to more sustained high-level expression.3 For hemophilia A treatment, Ad vectors are particularly useful, since the liver naturally produces factor VIII, and following intravenous (i.v.) injection, Ad vectors concentrate in the liver. This makes the gene transduction efficiency to liver very high. Adenovirus vectors have been developed for gene therapy due to their high titer, broad infectivity, potential for large payload, and in vivo gene delivery capacity.4 Although the immunogenicity and cytotoxicity associated with the early-generation Ad vectors have been a concern with respect to their clinical application, newly developed vectors, in which the viral coding sequences have been deleted, have significantly reduced the side effects associated with the vectors. The “gutless” Ad vector, or so called helper-dependent, large-capacity, or mini- Ad vectors are the representative examples of these new-generation Ad vectors.5-15 The mini-Ad vector system described in this report was developed based on two major research findings. First, an Ad- SV40 hybrid virus discovered during attempts to grow human Ad in non-permissive monkey COS-7 cells.16 The hybrid virus had a genome structure in which only both ends of the Ad sequences were retained and almost all coding sequences of the Ad genome were replaced by symmetric, tandemly repeated SV40 genomes. The hybrid viruses replicated and were packaged in the presence of a wild-type Ad as a helper. This finding implied that total replacement of the Ad genome was possible to form a mini-Ad vector as long as proper helper function and selective pressure was provided. Secondly, it was discovered that Ad packaging can be attenuated by deleting portions of the packaging signal.17 This finding provided a means to put selective pressure on the helper Ad (referred to as ancillary Ad) by specifically limiting its packaging process and allowing a preferential packaging of the mini-Ad. The system, therefore, is designed to have three main components: the mini-Ad vector, the E1-deleted ancillary Ad, and a production cell line that provides AdE1 complementation. Based on the mini-Ad vector system, MiniAdFVIII was developed. The MiniAdFVIII vector carries a 27 kb expression cassette, in which the full-length human factor VIII cDNA is flanked by a human albumin promoter and cognate genomic sequences. Infection of MiniAdFVIII in vitro showed that the vector mediated expression of functional human factor VIII at levels of 100-200 ng/106 cells per 24 hours in HepG2 and 293 cells. With single-dose intravenous injection of 1011 viral particles in hemophilic mice, MiniAdFVIII produced a sustained high-level expression of human factor VIII (at 100-800 ng/ml for up to 369 days) that corrected the factor VIII-deficient phenotype. Safety studies of MiniAdFVIII showed that there were no significant toxicities in mice and dogs after a single intravenous dose of up to 3×1011 and 6×1012 viral particles, respectively. In this report, other studies for developing the MiniAdFVIII vector with a site-specific integration capability and the development of a human factor VIII-tolerized mouse model for preclinical studies of MiniAdFVIII are described.

25 September 2023 in Diabetes mellitus
Verified
Journal Article
Open access
PDF file
MSMarina Shestakova
Marina Shestakova
VDVladimir Dobronravov
Vladimir Dobronravov
AAA. S. Ametov
A. S. Ametov
MAM. B. Antsiferov
M. B. Antsiferov
MBM. M. Batyushin
M. M. Batyushin
MSM. S. Shamkhalova
M. S. Shamkhalova
Chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) is one of the most important medical and social problems associated with significant risks for patients and a burden on the national healthcare system. There are significant unmet diagnostic and therapeutic needs of CKD in T2D patients in Russia relating to problems of underdiagnostics of CKD and substantial residual cardiorenal risks in these patients in spite of therapy with registered renoprotective medications. Finerenone is the first selective non-steroidal mineralocorticoid receptor antagonist which targets different from other drugs pathways involved in the pathogenesis of CKD in T2D. It has a significant potential to reduce residual renal and CV risks, and therefore addresses the existing therapeutic unmet need. According to the results of recent clinical studies, the cardio- and renoprotective effects of finerenone were apparent throughout a wide range of CKD C1-C4 in T2D patients, regardless of the severity of kidney dysfunction, the level of HbA1c and other drug therapy. This document summarizes the main results regarding the efficacy and safety profiles of finerenone and determines its place in treatment of CKD in T2D patients.

16 January 2016 in General Reanimatology
Verified
Journal Article
Open access
PDF file
OUO. N. Ulitkina
O. N. Ulitkina
ZFZh. S. Filippovskaya
Zh. S. Filippovskaya
EPE. I. Prokopenko
E. I. Prokopenko
AOA. M. Ovezov
A. M. Ovezov
VLValery V. Likhvantsev
Valery V. Likhvantsev
Цель. Показать сложности дифференциальной диагностики и лечения атипичного гемолитико-уремического синдрома на примере пациентки 23 лет. Результаты. Показана эффективность применения препарата Экулизумаб (Солирис, ДСМ Фармасьютиклс Инк., США) (гликозилированные гуманизированные моноклональные антитела к иммуноглобулинам IgG2/4k) при лечении этого заболевания. Заключение. Атипичный гемолитико-уремический синдром беременных – заболевание, сложность лечения котогого во многом связана с проблемами дифференциальной диагностики с тромботической тромбоцитопенической пурпурой и проявлениями полиорганной недостаточности. В лечении данного заболевания ключевая роль отводится препарату Экулизумаб.

1 January 2017 in Nephrology (Saint-Petersburg)
Verified
Journal Article
Closed access
PDF file
EPE. I. Prokopenko
E. I. Prokopenko
AVA. V. Vatazin
A. V. Vatazin
ESE. O. Shcherbakova
E. O. Shcherbakova
RKR. O. Kantariya
R. O. Kantariya
ПОСТТРАНСПЛАНТАЦИОННЫЙ САХАРНЫЙ ДИАБЕТ У РЕЦИПИЕНТОВ РЕНАЛЬНОГО ТРАНСПЛАНТАТА: ОПЫТ ОДНОГО ЦЕНТРА

10 May 2025 in Obstetrics, Gynecology and Reproduction
Verified
Journal Article
Open access
PDF file
EPE. I. Prokopenko
E. I. Prokopenko
INI. G. Nikolskaya
I. G. Nikolskaya
DGD. V. Gubina
D. V. Gubina
AVA. V. Vatazin
A. V. Vatazin
TKT. S. Kovalenko
T. S. Kovalenko
EEE. B. Efimkova
E. B. Efimkova
Introduction. Women with chronic kidney disease (CKD) have an increased incidence of pregnancy complications, but few comparative studies on features of pregnancy course during chronic glomerulonephritis (CGN) and chronic tubulointerstitial kidney disease (CTID) are available.Aim: comparison the frequency of pregnancy complications, proteinuria (PU) and serum creatinine dynamics in patients with CGN and CTID.Materials and Methods. We conducted an observational single-centre study enrolling 128 pregnant women with CGN (135 deliveries) and 138 with CTID (145 deliveries) by assessing the incidence of complications, diurnal PU, serum creatinine level starting from early gestation to delivery every 4–6 weeks.Results. Favourable pregnancy outcome was observed in 94.8 % of patients with CGN and in 95.7 % with CTID. The incidence of preeclampsia (PE), placental insufficiency, acute kidney injury, and preterm delivery showed no not inter-group differences, but arterial hypertension, PU > 1.0 g/day were more common in CGN, whereas in CTID – urinary tract infections. During pregnancy, PU increased in both groups, and only in CGN in patients with PE early pregnancy PU was significantly higher than in those without PE. Both groups showed similar serum creatinine dynamics: decrease starting from early pregnancy stages, stabilization in the middle of pregnancy followed by elevation from 28–30 weeks of gestational age until delivery.Conclusion. High PU level in early pregnancy may help to predict PE in CGN, but not in CTID. In patients with CKD, rise in PU along with serum creatinine increased up to baseline level in late pregnancy, are typically observed and without PE, fetal distress should not be considered as unambiguous indication for early delivery.

23 April 2023 in Russian Bulletin of Obstetrician-Gynecologist
Verified
Journal Article
Closed access
INI.G. Nikol’sKaya
I.G. Nikol’sKaya
SNS.V. Novikova
S.V. Novikova
EPE.I. Prokopenko
E.I. Prokopenko
NBN.V. Bychkova
N.V. Bychkova
PNP.P. Nefedov
P.P. Nefedov
TMT.A. Mar’yAnova
T.A. Mar’yAnova
Objective. Formation of an algorithm for the management of pregnant women with CKD to improve obstetric, perinatal and nephrological outcomes. Material and methods. The proposed algorithm for the management of pregnant women with chronic kidney disease is based on an analysis of the management and outcomes of pregnancy in 311 patients with CRF of different stages: 197 with stage I (CKD I), 46 with stage II (CKD II), 55 pregnant women with stage III (CKD III), 7 pregnant women with stage IV CKD (CKD IV), 6 pregnant women with end-stage CKD (CKD V) undergoing renal replacement therapy with hemodialysis. The key indicators of homeostasis have been identified on the basis of which dynamic monitoring should be carried out in this cohort of patients, and the effectiveness of the proposed management tactics has been proven. Results. The article substantiates the need for pregnancy planning in this group of women, presents the frequency of possible gestational complications, their prevention and treatment based on indicators of dynamic control of the main parameters of homeostasis developed for this contingent of patients. The criteria for predicting the outcome of pregnancy, conditions for prolongation of pregnancy in kidney diseases and medical indications for its artificial termination are presented, as well as methods of delivery are discussed. When using the proposed algorithm in patients with stages I and II of CKD, adverse pregnancy outcomes were absent, with stage III CKD, a 5-fold decrease in the total proportion of losses of desired pregnancies in all three trimesters was achieved (from 56.0 to 10.5%). In the group without this algorithm, the total proportion of losses in all trimesters of pregnancy corresponded to 49.4% in CKD I and 46.2% in CKD II. Conclusion. The presented algorithm for the management of pregnant women with CKD can significantly improve pregnancy outcomes in women with chronic kidney disease, even in the presence of chronic renal failure.